Menu
No results found.
Weekly Share Price & Valuation Overview
Shanghai General Healthy Information and Technology Co., Ltd.
Shanghai General Healthy Information and Technology Co., Ltd. provides pharmaceutical logistics automation, information technology, and intelligent and mobile medical solutions in China. The company's products include the Smart Pharmacy Project, an intelligent drug management system that combines software and hardware; intelligent static distribution center project, an intelligent intravenous drug configuration and management system; and Intelligent Drug Consumables Management Project, a management system for drug consumables, including poisonous hemp drugs and high-value medical consumables. The company was founded in 2014 and is based in Shanghai, China.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 3.18B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 3.32B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 359.78M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 125.27M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY 50.32M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 2.74
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.23
- Shares Outstanding
- 136.00M
- Float Shares
- 67.65M
- Implied Shares Outstanding
- 136.79M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
8.94%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
13.99%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
34.82%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
8.53%
- ROA Return on assets: net income ÷ total assets.
-
1.16%
- ROE Return on equity: net income ÷ shareholder equity.
-
2.75%
- Revenue Growth Year-over-year revenue growth.
-
1.16%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-25.00%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-34.60%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.95
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.12
- Total Cash Cash and equivalents.
- CNY 80.92M
- Total Debt Short + long-term interest-bearing debt.
- CNY 136.25M
- Net Debt Total debt − cash (negative = net cash).
- CNY 55.34M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 2.71
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY 53.56M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY -154.80M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
14.89%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-43.03%
- Cash Conversion (OpCF/EBITDA)
- 1.06
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.